Chung Wendy 4

What Happened Wendy Chung, a director of Prime Medicine, was granted a derivative award covering 75,000 shares reported on Form 4 for the transaction date 2026-06-05. The filing lists the acquisition as an award/grant (code A) with a reported price of $0.00 and total reported value $0 (derivative). This was a compensation grant (not a purchase or sale) and does not represent an immediate cash transaction or disposition.

Key Details

• Transaction date: 2026-06-05; Form 4 filed 2026-06-08 (Accession: 0001628280-26-041560)
• Transaction type: Grant / award of a derivative (code A)
• Shares/units granted: 75,000
• Reported price: $0.00; reported total value: $0 (derivative)
• Vesting footnote: Award vests in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to continuous service (per filing footnote)
• Shares owned after transaction: not specified in the provided excerpt

Context This filing documents an option/award grant rather than a market buy or sale. The footnote indicates the award vests in full by a specified future date or at the next annual meeting if the director remains in service. Such grants are typical components of director compensation and do not by themselves indicate immediate buying or selling activity.